Compare YUMC & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YUMC | WST |
|---|---|---|
| Founded | 1987 | 1923 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 18.7B |
| IPO Year | N/A | N/A |
| Metric | YUMC | WST |
|---|---|---|
| Price | $49.41 | $230.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $338.00 |
| AVG Volume (30 Days) | ★ 1.1M | 963.4K |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.90% | 0.38% |
| EPS Growth | ★ 6.57 | 0.17 |
| EPS | 2.40 | ★ 6.75 |
| Revenue | ★ $11,569,000,000.00 | $3,017,900,000.00 |
| Revenue This Year | $5.49 | $6.97 |
| Revenue Next Year | $5.76 | $6.27 |
| P/E Ratio | ★ $21.09 | $34.46 |
| Revenue Growth | 3.29 | ★ 4.92 |
| 52 Week Low | $41.00 | $187.43 |
| 52 Week High | $53.99 | $347.85 |
| Indicator | YUMC | WST |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 27.57 |
| Support Level | $48.53 | $232.06 |
| Resistance Level | $51.38 | $243.91 |
| Average True Range (ATR) | 1.03 | 9.07 |
| MACD | 0.17 | -3.59 |
| Stochastic Oscillator | 56.25 | 11.77 |
With more than 18,000 units and USD 12 billion in systemwide sales in 2025, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC and Pizza Hut, but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza. Yum China is a trademark licensee of Yum Brands, paying 3% of KFC and Pizza Hut's systemwide sales to the company it separated from 2016.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.